János László Tanyi MD, PhD
János László Tanyi MD, PhD
Scientific Program Co-Chair
Assistant Professor of Obstetrics and Gynecology, Gynecologic Oncology
University of Pennsylvania, Health System, Philadelphia, Pennsylvania
Dr. Tanyi received his medical degree at the University of Debrecen, Medical and Health Sciences Center in Hungary, summa cum laude. He completed his residency training in obstetrics and gynecology at the Baylor College of Medicine in Houston, and subsequently, a gynecologic oncology fellowship at University of Pennsylvania. Dr. Tanyi also has been obtained his PhD degree in 2008 at the Semmelweis University and Medical School at Budapest. Dr. Tanyi developed the novel hypothesis that the aberration in Lysophosphatidic acid (LPA; a cell membrane phospholipid metabolite that can act as an extracellular signal) metabolism in ovarian cancer may be the result of decreased metabolism which further stimulates ovarian cancer progression. He also validated LPA as an important therapeutic target. Dr. Tanyi was then recruited to the Department of Obstetrics and Gynecology and the Division of Gynecologic Oncology at The University of Pennsylvania as an assistant professor in 2011. Dr. Tanyi is board certified in Obstetrics and Gynecology and Gynecologic Oncology. Dr. Tanyi sees women with all gynecologic cancers and has extensive training in minimally invasive surgery, robotic surgery, extended pelvic resections, and pelvic reconstructive surgery. Dr. Tanyi’s clinical interests include complex gynecologic procedures mostly in advanced ovarian, fallopian tube and primary peritoneal malignancies. His clinical and translational research focuses primarily on tumor immunology and immunotherapy. This includes the mechanisms by which tumors escapes immune attack and the development of novel immunotherapies. These immunotherapies mostly individualized and the treatment is tailored to a patient’s cancer—such as dendritic cell vaccines and therapies that involve the manipulation and reinfusion of a patient’s T cells. Furthermore, Dr. Tanyi is involved in the development and application of the novel T cell technology called chimeric antigen receptor genetically engineered T cells.Dr. Tanyi has participated as a principal investigator in multipleclinical trials and laboratory investigations. He has authored over 80 scientific publications, 6 book chapters, given high number of invited lectures worldwide and nationwide. He also servesas a Scientific Reviewer to a number of major journals, such as Nature Communications, Science Translational Medicine, Journal of Immunotherapy, Journal of Gynecologic Oncology, PLoS One and Clinical Cancer Research. Dr. Tanyi has won numerous academic and scientific awards including multiple health care hero awards for outstanding patient care at the University of Pennsylvania Health System and the Angela Carlino Excellence in Ovarian Cancer Research and Care Award by Sandy Rollman Ovarian Cancer Foundation.